Corrigendum to “Insulin-like Growth Factor-binding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC)”

corrigendum

© The American Society of Gene & Cell Therapy

doi:10.1038/mt.2015.89

Corrigendum to “Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo” Michael C. Milone, Jonathan D. Fish, Carmine Carpenito, Richard G. Carroll, Gwendolyn K. Binder, David Teachey, Minu Samanta, Mehdi Lakhal, Brian Gloss, Gwenn Danet-Desnoyers, Dario Campana, James L. Riley, Stephan A. Grupp and Carl H. June Molecular Therapy (2009) 17: 1453–1464. doi:10.1038/mt.2009.83

The order of variable heavy (VH) and variable light chain (VL) domains of the anti-CD19 scFv depicted in the schematic of Figure 1a were reversed from the actual orientation used. The order of the domains should be VL followed by VH.

doi:10.1038/mt.2015.57

Corrigendum to “Insulin-like Growth Factorbinding Protein-7 (IGFBP7): A Promising Gene Therapeutic for Hepatocellular Carcinoma (HCC)” Dong Chen, Ayesha Siddiq, Luni Emdad, Devaraja Rajasekaran, Rachel Gredler, Xue-Ning Shen, Prasanna K Santhekadur, Jyoti Srivastava, Chadia L Robertson, Igor Dmitriev, Elena A Kashentseva, David T Curiel, Paul B Fisher and Devanand Sarkar Molecular Therapy (2013) 21: 758–766. doi:10.1038/mt.2012.282

There was an error in Figure 1b. The correct Figure 1b appears below.

Ad.I7-3d

Ad.I7-2d

Ad.I7-1d

Ad.vec

Control

HepG3 Ad.I7-3d

Ad.I7-2d

Ad.I7-1d

Control

Ad.I7-3d

Hep3B Ad.I7-2d

Ad.I7-1d

Ad.vec

Control

Huh7

Ad.vec

b

IGFBP7 EF1α

1278

www.moleculartherapy.org  vol. 23 no. 7, 1278 jul. 2015